Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

× No keyword cloud information.

11 in total

1. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.

Authors: Min Hee Lee; Seong Eun Lee; Dong Wook Kim; Min Jeong Ryu; Sung Jin Kim; Sung Joong Kim; Yong Kyoung Kim; Ji Hoon Park; Gi Ryang Kweon; Jin Man Kim; Jung Uee Lee; Valentina De Falco; Young Suk Jo; Minho Shong
Journal: J Clin Endocrinol Metab Date: 2010-10-06 Impact factor: 5.958

2. The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Authors: Jens E Meyer; Carsten Brocks; Hendrik Graefe; Carola Mala; Natalie Thäns; Markus Bürgle; Annette Rempel; Nicole Rotter; Barbara Wollenberg; Stephan Lang
Journal: Breast Care (Basel) Date: 2008-10-16 Impact factor: 2.860

3. Drug discovery: inhibitors that activate.

Authors: Karen Cichowski; Pasi A Jänne
Journal: Nature Date: 2010-03-18 Impact factor: 49.962

4. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors: C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal: J Clin Endocrinol Metab Date: 2006-05-09 Impact factor: 5.958

5. Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells.

Authors: Theodore S Nowicki; Nicolas T Kummer; Codrin Iacob; Nina Suslina; Steven Schaefer; Stimson Schantz; Edward Shin; Augustine L Moscatello; Raj K Tiwari; Jan Geliebter
Journal: Laryngoscope Date: 2010-07 Impact factor: 3.325

6. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Authors: Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy
Journal: J Clin Endocrinol Metab Date: 2010-04-14 Impact factor: 5.958

Review 7. Regulation of cell signalling by uPAR.

Authors: Harvey W Smith; Chris J Marshall
Journal: Nat Rev Mol Cell Biol Date: 2010-01 Impact factor: 94.444

8. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.

Authors: Theodore S Nowicki; Hong Zhao; Zbigniew Darzynkiewicz; Augustine Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal: Cell Cycle Date: 2011-01-01 Impact factor: 4.534

9. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.

Authors: Zita Dubauskas; Joy Kunishige; Victor G Prieto; Eric Jonasch; Patrick Hwu; Nizar M Tannir
Journal: Clin Genitourin Cancer Date: 2009-01 Impact factor: 2.872

10. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.

Authors: Martyn Frederickson; Owen Callaghan; Gianni Chessari; Miles Congreve; Suzanna R Cowan; Julia E Matthews; Rachel McMenamin; Donna-Michelle Smith; Mladen Vinković; Nicola G Wallis
Journal: J Med Chem Date: 2007-12-29 Impact factor: 7.446